Mission: To make liver health screening accessible, accurate, and affordable for every individual everywhere,”ultimately saving potentially millions of lives”.

The Opportunity We are building a select Advisory Board of medical, scientific, and healthcare innovation leaders to guide our next phase of growth. Advisors will play a key role in clinical validation, AI integration, and strategic partnerships across healthcare systems, research institutions, and payers.

As a Member of the Board of Advisors, you will provide high-level strategic insight into our clinical direction, help shape partnerships with hospitals and health plans, and contribute to HepaTrac’s mission to democratize early liver diagnostics.

Key Responsibilities

• Clinical & Scientific Guidance: Provide insight into non-invasive liver diagnostics, hepatology, or biomarker validation.
• AI & Technology and sensor development: Advise on integrating HepaTrac’s data outputs into existing healthcare workflows and telecare platforms.
• Strategic Partnerships: Facilitate introductions to healthcare systems, research institutions, or funding bodies.
• Regulatory Readiness: Offer feedback on FDA, CE, or other clinical validation strategies.
• Thought Leadership: Represent HepaTrac in relevant healthcare innovation forums, conferences, and collaborations.

Ideal Profiles

We’re especially looking for individuals with:

• 10+ years in hepatology, gastroenterology, biomedical engineering, or digital health innovation
• Experience in AI-enabled diagnostics, biosensor technologies, or remote patient monitoring
• Clinical research or regulatory experience in non-invasive diagnostic tools
• Strong academic or industry networks in liver health, AI healthcare, or medical device innovation
• Passion for advancing early disease detection and improving global access to care

Founding Team

Dr. Vinod Rustgi – Founder & Chairman Distinguished Professor of Medicine, Director of Hepatology, and Professor of Epidemiology at Rutgers Robert Wood Johnson Medical School. Former Medical Director of Liver Transplantation at the Thomas Starzl Transplant Institute (UPMC). Holds an MBA in Health Services Administration from Johns Hopkins University – Carey Business School.í

Daniel Kim- Founder & CEO 4x/CEO/Investor/Entrepreneur/Technologist. Started and exited multiple companies valued at over $500M.

Why Join HepaTrac

• Transformative Mission: Be part of the first integrated AI platform for early liver disease detection.
• Global Impact: Address a silent epidemic affecting 1 in 4 adults worldwide.
• High-Growth Market: Non-invasive diagnostic market projected to exceed $50B by 2030 .
• Investor Alignment: Transparent goals, clear milestones, and a working product roadmap.

Compensation & Engagement

• Equity compensation for advisory contribution
• 1–2 hours/month (virtual)
• Advisors may receive early access to invest in HepaTrac’s current SAFE round ($750K at $5M valuation)

Apply If You…

• Have expertise or network influence in clinical diagnostics, AI healthcare, or telemedicine
• Are passionate about accelerating early detection and prevention of liver diseases
• Can commit 1–2 hours/month to strategic guidance
• Would consider investing alongside other advisors and investors